


**Figure S1.** Flow chart of selection process


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Boogaerts 2001	+	+	+	⊖	⊖	+	+
Caselli 2012	?	?	+	?	⊖	+	+
Groll 2010	?	?	+	⊖	+	+	+
Jadhav 2012	+	?	+	?	+	+	+
Jeong 2016	+	+	+	?	+	+	+
Maertens 2010	+	+	+	+	+	+	+
Meunier 1989	?	?	+	+	⊖	+	+
Oyake 2015	+	?	+	+	+	+	+
Prentice 1997	+	+	+	?	+	+	+
Schiel 2006	+	?	+	+	+	+	+
Schuler 2007	+	?	+	+	+	+	+
Viscoli 1996	+	+	+	⊖	+	+	+
Walsh 1999	+	+	+	+	+	+	+
Walsh 2002	+	+	+	+	+	+	+
Walsh 2004	+	+	+	+	+	+	+
Wang 2007	?	?	+	⊖	+	+	+
Wingard 2000	?	?	+	+	+	+	+

**Figure S2.** Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Boogaerts 2001[17]; Caselli 2012[18]; Groll 2010[19]; Jadhav 2012[20]; Maertens 2010[21]; Meunier 1989[22]; Oyake 2015[23]; Prentice 1997[24]; Schiel 2006[25]; Schuler 2007[26]; Viscoli 1996[27]; Walsh 1999[28]; Walsh 2002[29]; Walsh 2004[30]; Wang 2007[31]; Wingard 2000[32]; Jeong 2016[33]




**Figure S3.** Forest plot of itraconazole versus conventional amphotericin B on all-cause mortality  
AmB: Conventional amphotericin B




**Figure S4.** Forest plot of itraconazole versus conventional amphotericin B on fungal infection-related mortality


AmB: Conventional amphotericin B




**Figure S5.** Forest plot of itraconazole versus conventional amphotericin B on treatment response  
 AmB: Conventional amphotericin B



**Figure S6.** Forest plot of liposomal amphotericin B 3 mg/kg/day versus caspofungin on all-cause mortality  
 L-AmB: Liposomal amphotericin B




**Figure S7.** Forest plot of liposomal amphotericin B 3 mg/kg/day versus caspofungin on treatment response  
 L-AmB: Liposomal amphotericin B



**Figure S8.** Forest plot of liposomal amphotericin B 3 mg/kg/day versus conventional amphotericin B on all-cause mortality


L-AmB: Liposomal amphotericin B; AmB: Conventional amphotericin B






**Figure S9.** Forest plot of liposomal amphotericin B 3 mg/kg/day versus conventional amphotericin B on treatment response

L-AmB: Liposomal amphotericin B; AmB: Conventional amphotericin B




**Figure S10.** Forest plot of liposomal amphotericin B 3 mg/kg/day versus liposomal amphotericin B 1 mg/kg/day on treatment response  
 L-AmB: Liposomal amphotericin B




**Figure S11.** Forest plot of conventional amphotericin B versus liposomal amphotericin B 1 mg/kg/day versus on treatment response

AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B



**Figure S12.** A schematic of the network of evidence for all-cause mortality


ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT: No antifungal treatment



**Figure S13.** A schematic of the network of evidence for fungal infection-related mortality


ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT:

No antifungal treatment



**Figure S14.** A schematic of the network of evidence for treatment response


ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT: No antifungal treatment



**Figure S15.** Rank probability plot of antifungals for treatment response in subgroup analysis of non-allogenic haematological stem cell transplantation


AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT: No antifungal treatment

Rank 1 is best, rank 8 is worst.




**Figure S16.** Rank probability plot of antifungals for treatment response in subgroup analysis of adults  
 AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT: No antifungal treatment  
 Rank 1 is best, rank 9 is worst.







**Figure S17.** Rank probability plot of antifungals for treatment response in subgroup analysis of pediatrics  
 AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B; NAT: No antifungal therapy  
 Rank 1 is best, rank 5 is worst.



**Figure S18.** Rank probability plot of antifungals for all-cause mortality in sensitivity analysis  
 ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B  
 Rank 1 is worst, rank 8 is best.



**Figure S19.** Rank probability plot of antifungals for fungal infection-related mortality in sensitivity analysis  
 ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B  
 Rank 1 is worst, rank 7 is best.



**Figure S20.** Rank probability plot of antifungals for treatment response in sensitivity analysis  
 ABLC: Amphotericin B lipid complex; AmB: Conventional amphotericin B; L-AmB: Liposomal amphotericin B  
 Rank 1 is best, rank 8 is worst.